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The aim of this study was to evaluate the efficacy and the toxicity of a full dose of gemcitabine and a single dose of cisplatin with
concurrent radiotherapy in patients with locally advanced pancreatic cancer. Forty-one patients with locally advanced pancreatic
cancer were enrolled. Patients received gemcitabine (1000mgm
 2 on days 1, 8, 15, 29, and 36) and cisplatin (70mgm
 2 on days 1
and 29) with concurrent radiotherapy (45Gy in 25 fractions). Treatment was completed in 38 out of 41 patients (92.7%). The overall
response rate was 24.4% (two complete and eight partial). Six patients (14.6%) underwent definite pancreatic resection and four had
negative surgical margins. The intention of the treatment analysis showed that the median survival time and median time to tumour
progression were 16.7 and 8.9 months. The 1- and 2-year survival rates were 63.3 and 27.9%, respectively. Overall survival was
significantly longer in the low baseline CA19-9 group and therapeutic responders. Toxicities were tolerable and successfully managed
by conservative treatments. The therapeutic scheme of a weekly full dose of gemcitabine and a single dose of cisplatin combined with
external radiation is effective and might prolong the survival of patients with locally advanced pancreatic cancer.
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Pancreatic cancer is a leading cause of cancer-related mortality in
western countries and accounts for approximately 30000 deaths
each year in the United States (Jemal et al, 2005). In Korea,
pancreatic cancer accounts for the eighth highest cancer incidence
and the fifth highest cancer-related mortality (Ministry of Health
and Welfare Republic of Korea, 2007). Surgical resection is the
only potentially curative therapy, but only 10–20% of patients
qualify for the procedure (Kalser et al, 1985). The invasion of
pancreatic cancer into the major vessels is the main reason why
resections cannot be performed. Approximately 30% of patients
are diagnosed with locally advanced disease at initial presentation
(Moertel et al, 1981). In this group of patients, there are several
reports of favourable results with concurrent chemoradiotherapy.
Gastrointestinal Tumor Study Group (1979, 1988) (GITSG) trials
demonstrated a survival benefit for patients with locally advanced
pancreatic cancer who were treated by external beam radiotherapy
and 5-fluorouracil (5-FU) compared with patients who were
treated by radiotherapy alone (Moertel et al, 1981). In recent
decades, 5-FU has been considered the standard cytotoxic agent
and radiosensitiser for use with concurrent radiotherapy. Since
1996, gemcitabine, a pyrimidine analogue and potent radio-
sensitiser, has been studied as a substitute for 5-FU in treatments
using concurrent chemoradiotherapy (Blackstock et al, 1999;
McGinn et al, 2001). Recent phases I and II studies on
gemcitabine-based chemoradiotherapy were feasible and improved
therapeutic response and survival (Blackstock et al, 1999; McGinn
et al, 2001; Okusaka et al, 2004; Magnino et al, 2005).
Many studies have been performed to increase the objective
response rate (ORR) and overall survival (OS) by mixed regimens
consisting of gemcitabine with other drugs. The combination of
gemcitabine and cisplatin has a synergistic effect in vitro in which
gemcitabine can inhibit the DNA repair mechanism after cisplatin-
induced damage, and cisplatin influences gemcitabine metabolism
through the inhibition of ribonucleotide reductase (Peters et al,
1995; Bergman et al, 1996). A recent phase III trial with
gemcitabine (1000mgm
 2) and cisplatin (50mgm
 2) on days 1
and 15 of a 4-week cycle showed favourable median OS and
median time to tumour progression (TTP) compared with
gemcitabine alone in advanced pancreatic cancer (Heinemann
et al, 2006). We recently reported the feasibility and clinical
efficacy of cisplatin combined with weekly gemcitabine treatments
for patients with metastatic pancreatic cancer (Bang et al, 2006b).
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sIn the present study, we evaluated the efficacy and toxicity of
concurrent chemoradiotherapy with a full dose of gemcitabine and
a single dose of cisplatin in patients with locally advanced
pancreatic cancer. The primary end point of this study was the
survival rate, whereas the secondary end points were ORR, TTP,
and side effects.
MATERIALS AND METHODS
Eligibility criteria
Patients were recruited from January 2000 to December 2005 at the
Center for Gastrointestinal Diseases at Severance Hospital in Seoul,
Korea. Seven inclusion criteria were used for enrollment: (1)
patients must have a newly diagnosed and pathologically confirmed
locally advanced pancreatic adenocarcinoma. We defined this
cancer stage as when the tumour encases the superior mesenteric
arteries or coeliac axis, or occludes the superior mesenteric–portal
vein confluence. In these cases, we found no evidence of distant
metastatic diseases based on physical examination and radio-
graphic imaging, including positron emission tomography (PET)
scans. The tumours were staged according to the American Joint
Committee on Cancer (AJCC) staging system (6th edition). (2)
Patients must be between the ages of 18–75 years. (3) Patients must
also have an Eastern Cooperative Oncology Group (ECOG)
performance status of 0–2; (4) adequate bone marrow function
(white blood cell count X4000mm
 3, absolute neutrophil count
X1500mm
 3, haemoglobin X10g per 100ml, and platelet count
X100000mm
 3); (5) adequate hepatic function (alanine transa-
minase or aspartate transaminase levels o5 times the upper limit
of institutional normal and bilirubin levels o3mg per 100ml with
adequate biliary decompression); (6) adequate renal function
(serum creatinine o2mg per 100ml); and (7) adequate cardio-
pulmonary function. Patients were ineligible if they had a
concurrent type of malignancy, experienced recent upper gastro-
intestinal bleeding, or any other underlying serious medical
conditions that would interfere with the study. This study was
approved by the Institutional Review Board of Severance Hospital.
We fully informed all patients about the nature and purpose of the
study and all patients gave written informed consent.
Treatment plan
The protocol consisted of a 5-week course of external radiotherapy
and concurrent chemotherapy with gemcitabine and cisplatin.
Chemotherapy began on the 1st day of radiotherapy: 1000mgm
 2
of gemcitabine was delivered intravenously for 30min on days 1, 8,
15, 29, and 36, while 70mgm
 2 of cisplatin was delivered
intravenously for 2h on days 1 and 29. Radiotherapy was
administered by linear accelerator (CLINAC 2100C; Varian
Medical Systems, Palo Alto, CA, USA) using three-dimensional
conformal technique. A total radiation dose of 45Gy was delivered
with daily doses of 180cGy for five fractions each week. Gross
target volume (GTV) was confined to primary tumour and any
regional lymph nodes over 10mm detected by computed
tomography (CT). Clinical target volume (CTV) was defined as
GTV plus primary echelon lymph node according to tumour
location. Planning target volume was defined as CTV plus 0.5cm
margin to cover organ motion and daily set-up error. The four
parallel opposing fields (anterior, posterior, and opposed lateral
fields) were used, and the radiation dose to the adjacent organs
was limited as follows: liver p30Gy, kidneys p20Gy, and spinal
cord p45Gy).
Response assessments and maintenance therapy
The primary end point of this study was survival rate, and the
secondary end points were ORR (complete response (CR)þpartial
response (PR)), TTP, and side effects. All patients underwent a
pretreatment evaluation consisting of medical history, physical
examination, laboratory tests including serum carbohydrate
antigen (CA) 19-9, chest X-rays, and high-resolution pancreatic
CT scans. These tests were performed within 2 weeks before the
start of treatment. Positron emission tomography scans were
performed to exclude distant metastases. Endoscopic retrograde
cholangiopancreatography and biliary drainage procedures were
performed if necessary.
Four weeks after completion of radiotherapy, therapeutic
responses were evaluated according to the World Health
Organization (WHO) criteria by using chest X-rays and helical
CT scans (World Health Organization, 1979). A CR was defined as
the disappearance of all measurable or evaluable diseases for a
minimum of 4 weeks. Partial response was defined as a 450%
reduction in the sum of the products of the perpendicular
diameters of all measurable lesions for at least 4 weeks. SD was
defined as a o50% reduction or a o25% increase in the sum of
the products of the two perpendicular diameters of all measured
lesions. Progressive disease (PD) was defined as a 425% increase
in the sum of the products of the two perpendicular diameters of
all lesions or the appearance of any new malignant disease.
Patients who did not receive objective evaluations were regarded as
PD. If the residual tumours became resectable after chemor-
adiotherapy, radical resections were performed. Patients with
unresectable tumours received maintenance chemotherapy, which
was gemcitabine (1000mgm
 2 weekly followed by 1 week of rest)
and cisplatin (75mgm
 2 on day 1, every 4 weeks). Treatment with
gemcitabine and cisplatin continued until there was evidence of
disease progression or significant clinical deterioration. Follow-up
evaluations were performed every third cycle. Time to tumour
progression was calculated from the time of entry into the study
until disease progression, and OS was calculated from study entry
to death or the last follow-up visit.
Toxicity and dose adjustment
During chemoradiotherapy, all patients visited the clinic every
week and had blood samples taken every 2 weeks for toxicity
evaluations. Toxicity was evaluated according to the National
Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0.
The gemcitabine and cisplatin doses were reduced for toxicity on
the day of treatment as follows: 75% of the drug dosage was given
to patients with an absolute neutrophil count of 500–900mm
 3 or
with a platelet count of 50000–74000mm
 3, and doses were
reduced 50% if patients had an absolute neutrophil count of less
than 500mm
 3 or a platelet count of 50000mm
 3. For patients
with WHO grades 3–4 nonhaematological toxicity (excluding
nephrotoxicity), doses were reduced 75% for those with grade 3
nonhaematological toxicity (except nausea/vomiting and alopecia)
and 50% for those with grade 4 nonhaematologic toxicity (except
nausea/vomiting and alopecia). Radiation therapy was stopped
when patients experienced grades 3–4 gastrointestinal toxicities or
grade 4 haematological toxicities. Treatments were completely
stopped after a second interruption caused by haematological
toxicity.
Statistical analysis
Objective responses were reported according to an intention-to-
treat basis. On the basis of the most conservative assumption of a
30% survival rate at 1 year (null hypothesis) in historic controls
with locally advanced pancreatic cancer (Okusaka et al, 2004), an
increase of 50% or more (alternative hypothesis) could be shown
with a power of 80% by investigating a sample size of at least 35
patients (a¼0.05, one-sided test) (A’Hern, 2001). Overall survival
and TTP were analysed using Kaplan–Meier method with 95%
confidence intervals (CIs). The univariate analysis to identify
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sparameters predicting survival was performed by computing
survival curves using Kaplan–Meier method. A P-value of less
than 0.05 was considered to be statistically significant. When using
CA19-9 levels to predict survival, we excluded patients with serum
bilirubin levels that were higher than 3mg per 100ml at the time
when CA19-9 measurements were taken. All statistical analyses
were performed with commercially available software (SPSS
version 13.0; SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
From January 2000 to December 2005, 41 patients were enrolled in
the study. The baseline characteristics of patients are summarised in
Table 1. The patient group had 22 men and 19 women with a
median age of 59 years (range: 37–72 years). Fifteen patients
(36.6%) showed obstructive jaundice at diagnosis and their median
serum bilirubin level was 7.0mg per 100ml (range: 2.5–24.3mg per
100ml). Endoscopic biliary drainage with a plastic stent was
performed on 13 patients while percutaneous biliary drainage was
performed on 2 patients. Thirty-three patients (80.5%) had elevated
CA19-9 levels (437Uml
 1) upon initial diagnosis with the median
CA19-9 level at 686Uml
 1 (range: 51–20000Uml
 1). The median
follow-up period was 15.6 months (range: 5.5–52.4 months).
Objective responses, TTP, and OS
Of the 41 patients, 38 (92.7%) received scheduled chemoradiother-
apy. Two patients could not complete the treatment schedule due
to poor general conditions and one patient due to liver abscess. In
all, 40 out of the 41 enrolled patients (97.6%) received an objective
response evaluation and 1 patient was unable to be evaluated for
response due to withdrawal from treatment before re-evaluation.
This patient was considered to have PD.
Responses were analysed on an intention-to-treat basis. The
ORR was 24.4% while CR and PR were achieved in two patients
(4.9%) and eight patients (19.5%), respectively. Twenty-six
patients (63.4%) and five patients (12.2%) showed SD and PD,
respectively. Among the four out of five patients who can be
evaluated for PD, two had lung metastasis and 2 had metastasis to
the liver and multiple lymph nodes. When considering only the
primary pancreas tumours, two patients had PR, and two patients
had SD. Among the 20 patients who could be evaluated for serum
CA19-9 levels, 4 (20%) had normalised CA19-9 levels and 12 (60%)
achieved more than a 25% reduction in CA19-9 levels after
chemoradiotherapy. After completion of chemoradiotherapy, six
patients (14.6%) underwent surgery, four had R0 resections
(margin negative), and two had R1 resections with positive
margins. In all, 25 (83.3%) out of 30 patients without surgery
received maintenance chemotherapy with a median of 3 cycles
(range: 1–9 cycles).
The median survival time of the 41 enrolled patients was 16.7
months (95% CI: 10.4–23.1 months) (Figure 1A). The median OS
Table 1 Patient characteristics
Variable No. of patients (%)
Enrolled patients 41
Age (years)
Median (range) 59 (37–72)
Sex
Male 22 (53.7)
Female 19 (46.3)
Performance status
ECOG, 0–1 23 (56.1)
ECOG, 2 18 (43.9)
Diabetes mellitus 13 (31.7)
Symptoms at baseline
Abdominal pain 31 (75.6)
Jaundice 15 (36.6)
Weight loss 22 (53.7)
Tumour site
Head 26 (63.4)
Body 12 (29.3)
Tail 3 (7.3)
Tumour size (longest diameter, cm)
Median (range) 3.2 (1.5–9.0)
Tumour stage
IIA 8 (19.5)
IIB 3 (7.3)
III 30 (73.2)
CA 19-9 (Uml
 1) increased 33 (80.5)
Median (range) 686 (51–20000)
ECOG¼Easter Cooperative Oncology Group.
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Figure 1 Overall survival (A) and TTP (B) of the enrolled 41 patients.
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sof resected and unresected patients was 21.7 months (95% CI:
14.1–29.3 months) and 12.6 months (95% CI: 7.5–17.7 months),
respectively (P¼0.079). The 1- and 2-year cumulative survival
rates were 63.3 and 27.9%, respectively. The median TTP was 8.9
months (95% CI: 7.0–10.7 months) (Figure 1B).
Survival predictor
The prognostic factors influencing the patients’ cumulative
survival were analysed (Table 2). Univariate analysis revealed four
significant predictors of survival: performance status (P¼0.002),
baseline weight loss (P¼0.022), baseline serum CA19-9
levels (P¼0.004), and objective therapeutic response (P¼0.019)
(Figure 2).
Toxicity
All 41 patients enrolled in the study were assessed for toxicity.
Grades 3–4 toxicities included neutropaenia (26.9%), thrombo-
cytopaenia (19.5%), nausea/vomiting (22%), diarrhoea (4.9%), and
infection (2.4%) (Table 3). No treatment-related deaths occurred.
Thirty-eight (92.7%) patients received full-dose radiotherapy
(45Gy), and three patients (7.3%) received a 75% reduced dose
of gemcitabine and cisplatin due to myelosupression. One patient
was hospitalised due to duodenal ulcer bleeding after completion
of chemoradiotherapy.
DISCUSSION
Chemoradiotherapy affects the local control of a main tumour and
downstages the primary tumour by reducing the tumour size,
nodal involvement, and vascular invasion. Primarily unresectable
pancreatic cancer might converge into a resectable tumour after
Table 2 Parameters influencing cumulative survival of patients analysed
by univariate analysis
Parameters
Median survival
time (months)
95% CI
(months) P-value
Age 0.572
o60 15.6 8.6–22.7
X60 16.7 8.0–25.5
Sex 0.167
Male 20.6 10.3–31.0
Female 12.6 4.2–21.0
Performance status 0.002
ECOG, 0–1 20.1 16.8–23.4
ECOG, 2 10.8 6.0–15.5
Weight loss, baseline 0.022
None 20.3 16.2–24.5
1–5kg 16.7 1.6–31.8
6–10kg 12.6 5.4–19.7
410kg 6.0 0–13.8
Tumour site 0.152
Head 20.2 13.8–26.7
Body-tail 11.9 8.1–15.7
Tumour size
X5cm 20.1 0.7–39.6 0.137
o5cm 15.9 10.7–21.2
T stage 0.556
T3 18.3 7.8–28.7
T4 15.9 10.9–21.0
N stage 0.992
N1 15.6 6.1–25.2
N0 16.7 10.1–23.3
CA19-9, baseline 0.004
o1000Uml
 1 20.1 16.2–24.1
X1000Uml
 1 8.2 6.3–10.0
Objective response 0.019
CR+PR 18.3 6.2–30.3
SD 16.7 13.4–20.1
PD 7.5 5.9–9.2
Surgery 0.079
Yes 21.7 14.1–29.3
No 12.6 7.5–17.7
CR¼complete response; ECOG¼Easter Cooperative Oncology Group; PD¼
progressive disease; PR¼partial response; SD¼stable disease.
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Figure 2 Cumulative survival of patients based on baseline CA19-9 level
(A) and objective response (B). The median survival time of patients with
baseline CA19-9 level less than 1000Uml
 1 and more than 1000Uml
 1
were 20.1 and 8.2 months, respectively. The median survival time of
patients with objective response (CRþPR), SD, and PD were 18.3, 16.7,
and 7.5 months, respectively.
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schemoradiotherapy, potentially allowing the patient to expect
long-term survival after curative resection (Snady et al, 2000;
Ammori et al, 2003). In a chemoradiotherapeutic setting, the
chemotherapeutic agent should be a potent radiosensitiser to
maximise the therapeutic gain of radiotherapy on primary
tumours and have a systemic cytotoxicity to reduce the early
metastasis of pancreatic cancer (Moertel et al, 1981; Blackstock
et al, 1999).
In the present study, we used a combination of gemcitabine and
cisplatin with concurrent radiotherapy. Although we found no
consensus between administration schedules for gemcitabine with
radiation, recent studies have used twice weekly or weekly
administrations of gemcitabine for their main therapeutic
schedules (Blackstock et al, 1999; McGinn et al, 2001; Okusaka
et al, 2004; Magnino et al, 2005). According to the fact that patients
with resectable pancreatic cancer developed early recurrence after
surgery due to micrometastases and distant early metastases were
important cause of treatment failure of chemoradiotherapy in
patients with locally advanced pancreatic cancer, we used weekly
gemcitabine treatments in our study (Yeo et al, 1997; Paulino and
Latona, 2000). This schedule provided a modest local control and
systemic cytotoxicity compared with biweekly administration,
which was primarily focused on the effect of the radiosensitiser.
In addition, we used a full dose of gemcitabine (1000mgm
 2)t o
maximise systemic cytotoxicity. Although most of the recent
phases I and II studies were performed using a submaximal dose of
gemcitabine with radiotherapy, a study by McGinn et al (2001)
reported that the standard full dose of gemcitabine was acceptable.
Our previous experience also showed that radiotherapy with a full
dose of gemcitabine was tolerable (Chung et al, 2004).
Many attempts have been made to increase the ORR and OS by
exploring the combination of gemcitabine with other chemother-
apeutic agents. In this study, we used a single dose of cisplatin
combined with gemcitabine. There is a report that median TTP
and ORR were significantly improved with combined chemother-
apy of gemcitabine and cisplatin in patients with locally advanced
and metastatic pancreatic cancer (Colucci et al, 2002; Heinemann
et al, 2006). Recent phases I and II trials of chemoradiotherapy
with a combination of gemcitabine and cisplatin in locally
advanced pancreatic cancer patients used a divided dose of
cisplatin (Brunner et al, 2003; Wilkowski et al, 2004; Haddock
et al, 2007). However, in a study by Shepherd et al, cisplatin was
administered in a single dose over a 4-week cycle, and therapeutic
effect was superior over divided dose administrations in patients
with non-small cell lung cancer.
Previous phases I and II studies were performed with radio-
therapy doses of 42–50.4Gy and sometimes used boosting doses to
achieve local control (Blackstock et al, 1999; McGinn et al, 2001;
Brunner et al, 2003; Okusaka et al, 2004; Magnino et al, 2005). In
the present study, we used radiation doses of 45Gy with 25
fractions. Although four out of five patients with PD who could be
evaluated had metastatic disease, two had PR and two had SD of
the primary tumour after chemoradiotherapy. Our therapeutic
schedule and regimen showed good local control and demon-
strated that the treatment failure by concurrent chemoradiother-
apy on locally advanced pancreatic cancer was caused not by local
progression but early metastasis. These results are consistent with
a previous study (Paulino and Latona, 2000).
We summarised recent phase II trials on chemoradiotherapy
combined with gemcitabine alone or gemcitabine plus cisplatin in
locally advanced pancreatic cancer (Table 4) (de Lange et al, 2002;
Li et al, 2003; Okusaka et al, 2004; Wilkowski et al, 2004; Magnino
et al, 2005; Haddock et al, 2007). Compared with the recent phase
II study by Haddock et al, although the dose and cycle differed
from our study, 24.4% ORR and 16.7 months median survival time
of our study showed favourable results.
The major grades 3 and 4 toxicities were haematologic and
gastrointestinal toxicities when gemcitabine was combined with
radiotherapy. Rates of grades 3 and 4 toxicity in the present study
were similar to other reports of gemcitabine-based chemo-
radiotherapy (Blackstock et al, 1999; McGinn et al, 2001; Brunner
et al, 2003; Okusaka et al, 2004; Magnino et al, 2005). In the
present study, grades 3 and 4 neutropaenia occurred in 26.9% of
patients and was reversible with conservative therapy. Substantial
deterioration of general conditions owing to nausea or vomiting
was a major gastrointestinal problem during chemoradiotherapy,
and two patients did not complete the scheduled radiation due to
gastrointestinal toxicity. Some reports showed fatal gastrointest-
inal toxicity, especially ulceration and bleeding of the duodenum
(McGinn et al, 2001; Brunner et al, 2003). We observed one patient
(2.4%) with duodenal ulcer bleeding after completion of chemo-
radotherapy who was treated conservatively. Five other patients
(12.2%) with gastric or duodenal ulcer were also successfully
Table 3 Treatment-related toxicities according to WHO toxicity criteria
No. of patients (%)
Toxicities Grade 1 Grade 2 Grade 3 Grade 4
Haematology
Neutropaenia 9 (22.0) 11 (26.8) 7 (17.1) 4 (9.8)
Anaemia 12 (29.3) 24 (58.5) 0 (0) 0 (0)
Thrombocytopaenia 18 (43.9) 7 (17.1) 8 (19.5) 0 (0)
Nonhaematology
Nausea/vomiting 7 (17.1) 7 (17.1) 9 (22.0) 0 (0)
Mucositis 5 (12.2) 2 (4.9) 0 (0) 0 (0)
Diarrhoea 1 (2.4) 2 (4.9) 2 (4.9) 0 (0)
Gastric ulcer 0 (0) 3 (7.3) 0 (0) 0 (0)
Duodenal ulcer 0 (0) 2 (4.9) 1 (2.4) 0 (0)
AST/ALT 3 (7.3) 6 (14.6) 0 (0) 0 (0)
Neuropathy 0 (0) 1 (2.4) 0 (0) 0 (0)
Hypersensitivity 3 (7.3) 1 (2.4) 0 (0) 0 (0)
Infection 1 (2.4) 2 (4.9) 1 (2.4) 0 (0)
ALT¼alanine transaminase; AST¼aspartate transaminase.
Table 4 Summary of phase II trials of chemoradiotherapy combined with gemcitabine alone or gemcitabine plus cisplatin in locally advanced pancreatic
cancer
Study
No. of
patients
Chemotherapy
dose (mgm
 2)
RT dose
(Gy)
CR+PR
(%)
Median TTP
(months)
Median
OS (months)
1-year
survival (%)
de Lange et al (2002) 24 G 300 weekly per 3 weeks 24 29.2 7 10 —
Li et al (2003) 18 G 600 weekly per 6 weeks 50.4–61.2 50 7.1 14.5 —
Wilkowski et al (2004) 47 G 300, C 30 weekly per 4 weeks 45–50 68 7.8 10.7 —
Okusaka et al (2004) 42 G 250 weekly per 6 weeks 50.4 21 4.4 9.5 28
Magnino et al (2005) 23 G 50, 100 biweekly per 5 weeks 45 22 — 14 —
Haddock et al (2007) 48 G 30, C 10 biweekly per 3 weeks 50.4 8 7.3 10.2 40.4
C¼cisplatin; CR¼complete response; G¼gemcitabine; OS¼overall survival; PR¼partial response; RT¼radiotherapy; TTP¼time to progression.
Gemcitabine and cisplatin in locally advanced pancreatic cancer
SP Hong et al
885
British Journal of Cancer (2008) 98(5), 881–887 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
smanaged. In the setting of chemoradiation, cisplain-induced
neuropathy is not a major toxicity (Brunner et al, 2003; Haddock
et al, 2007). We had only one patient (2.4%) with grade 2
neuropathy during chemoradiation. During maintenance therapy,
grades 1–3 neuropathy occurred in 12.1% of patients.
In the present study, we demonstrated that performance status,
baseline weight loss, baseline serum CA19-9 level, and objective
therapeutic response were significant predictors of survival by
univariate analysis. A recent study by Ferrone et al (2006) reported
that preoperative CA19-9 levels could be used as predictors of
survival in patients with resectable pancreatic cancer. Their work
showed that the cutoff level of 1000Uml
 1 had a strong correlation
with survival (Ferrone et al, 2006). We showed that patients with
less than 1000Uml
 1 of baseline serum CA19-9 level were long-
term survivors.
We performed PET scanning to evaluate distant metastasis in all
enrolled patients. Our previous report demonstrated that initial
stages using CT scan were changed in 26.9% patients with
pancreatic cancer after PET scan (Bang et al, 2006a). Positron
emission tomography scans showed high sensitivity and specificity
in detecting metastatic disease, including liver, lungs, and
peritoneum (Pakzad et al, 2006; Bang et al, 2006a). Initial staging
workup, including PET scans, might be beneficial in selecting good
candidates for chemoradiotherapy in locally advanced pancreatic
cancer.
This study has a limitation of precise evaluation of resectability
of primary pancreatic cancer after chemoradiotherapy. Computed
tomography scans make it difficult to differentiate remnant
tumours with radiation-induced change in re-staging after
chemoradiotherapy. A previous study showed that SD re-staged
by CT scan revealed pathological PR after laparotomy (Mornex
et al, 2006).
In conclusion, we demonstrated the clinical efficacy and
tolerability of treating locally advanced pancreatic cancer with a
weekly full dose of gemcitabine and a single dose of cisplatin with
concurrent radiotherapy. Combining chemotherapeutic agents are
important to achieve not only local control but also good systemic
cytotoxicity in patients with locally advanced pancreatic cancer.
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